• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis Limited recognised as Gold Level Innovator by Innovate NI
Share
News

ProAxsis Limited recognised as Gold Level Innovator by Innovate NI

December 2, 2020
-
Posted by David Ribeiro

ProAxsis (www.proaxsis.com), the Belfast-based protease diagnostics company, is delighted to announce that it has been recognised as a Gold Level Innovator in the Innovate NI Innovation Accreditation programme. The company has been recognised due to it continually demonstrating its ability to transform innovate ideas into commercially successful products.

Speaking about the recognition, Dr David Ribeiro, CEO of ProAxsis, commented:

“Recognition of this kind from Innovate NI is a great testament to both the cutting-edge research being conducted by the ProAxsis team of scientists at our purpose-built laboratory in Belfast, and our ability to transition these exciting concepts in to commercially viable assets.  ProAxsis has conducted a number of R&D projects supported by Invest Northern Ireland, which have successfully led to the launch of highly novel protease biomarker assays, and we remain extremely grateful for their ongoing support in propelling the company towards being a globally-renowned protease diagnostics company.”

Innovate NI is a Department for the Economy programme, helping local businesses innovate successfully. It is delivered by Invest Northern Ireland, local councils and further education colleges.

Dr Vicky Kell, Invest NI’s Director of Innovation, Research & Development, added: “Over the last 5 years, we have worked in partnership with ProAxsis and our innovation support, including R&D, has helped it to develop and bring to market new diagnostic products which are now sold globally.   As this company has proven, innovation is the key to business resilience and growth and being recognised as a Gold level innovator is testament to the success of its innovation journey so far.  With this commitment to innovation, I am confident ProAxsis will continue to develop ground-breaking diagnostics, ultimately benefiting patients around the World.”

Any enquiries concerning ProAxsis’ work on protease biomarkers can be directed to info@proaxsis.com.

About ProAxsis

ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, and with a rapidly growing global client list of pharmaceutical companies and academic laboratories. The company has registered a CE Mark for activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis. 

This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels.  Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months. 

In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha.  Grant-funded R&D projects for a variety of targets remain a key area of focus.

Aside from the provision of assays, ProAxsis can offer sample analysis at its purpose-built laboratory facility in Belfast and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.

About Innovate NI

Innovate NI is a Department for the Economy programme, helping local businesses innovate successfully. It is delivered by Invest Northern Ireland, local councils and further education colleges.

December 2, 2020

Related News

Other posts that you should not miss.
News

ProAxsis builds market presence

June 20, 2016
-
Posted by Webmaster

ProAxsis (www.proaxsis.com) is undertaking business development activities with Invest Northern Ireland support. Speaking about the plans, Dr David …

Read More
June 20, 2016
Posted by Webmaster
News

ProAxsis expands inflammatory biomarker research via new partnership with Queen’s University Belfast

January 19, 2022
-
Posted by Jessica Robinson

ProAxsis Limited, the Belfast-based diagnostics company, today announces that in partnership with Dr Rich Williams, a Senior …

Read More
January 19, 2022
Posted by Jessica Robinson
News

ProAxsis announces new appointments

June 23, 2020
-
Posted by David Ribeiro

ProAxsis Limited, the Belfast-based diagnostics company, is pleased to welcome back Elisha Cain, who re-joins the company …

Read More
June 23, 2020
Posted by David Ribeiro
← PREVIOUS POST
ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19
NEXT POST →
ProAxsis Limited appoints distributor for key North America region
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
  • January 31, 2022
    ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis Limited recognised as Gold Level Innovator by Innovate NI - ProAxsis